Dr. Nader Al Nakouzi is a research scientist at the Vancouver Prostate Centre. He obtained a Doctor of Philosophy in cancer biology from the University of Paris-XI in 2011 and a specialized Master of Business Administration in pharmaceutical and health care management from ISC-Paris. From 2012 to 2016, he pursued his postdoctoral training with Drs. Martin Gleave and Mads Daugaard.
Dr. Al Nakouzi has a background in molecular and cell biology, with 10 years of experience in the development of cancer therapeutics and molecular mechanisms of drug resistance. Dr. Al Nakouzi’s primary research goal is to identify and characterize novel drug targets to treat late-stage prostate cancer. His ongoing research focuses on molecular and biochemical events underlying the prostate cancer progression, glycocalyx formation, chemotherapy resistance mechanisms and posttranslational modifications in cancer.
Dr. Al Nakouzi has published original research in top-tier scientific journals and received numerous national and international awards, including an ARC-Doctoral award-France, American Association for Cancer Research Scholar-in-Training award, Terry Fox Foundation Scholar-in-Training award, MITACS Elevate fellowship, CUA-Astellas grant, SPORE-NIH grant and Canadian Institutes of Health Research funding.
News and Awards
- Nature communications -
- Cancer cell -
- EMBO molecular medicine -
- European urology -
- The Journal of clinical investigation -